Key takeaways for Rhode Island
- • Wegovy is the FIRST weight-loss GLP-1 with an MACE-reduction indication (Mar 2024).
- • Ozempic carries a CV indication in T2D adults with established CVD.
- • SELECT showed 20% MACE reduction over roughly 3.3 years on Wegovy.
- • RIte Care coverage rules apply for Cardiovascular Risk Reduction patients in Rhode Island — see Medicaid section below.
- • 16 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Cardiovascular Risk Reduction
Multiple GLP-1 drugs have FDA-approved cardiovascular indications. In March 2024, Wegovy became the first weight-loss drug approved to reduce risk of major adverse cardiovascular events (MACE) — cardiovascular death, non-fatal MI, non-fatal stroke — in adults with established CVD and obesity/overweight. Ozempic carries an MACE-reduction indication in T2D adults with established CVD. Evidence grade: A (large outcomes trials). Trulicity (dulaglutide) has a similar T2D CV indication via REWIND. These indications are based on dedicated CV outcomes trials, not extrapolation.
Rhode Island-specific context
Rhode Island has telehealth access concentrated in Providence, Warwick, Cranston metros, with additional reach to Pawtucket and East Providence. Lifespan, Care New England is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.ri.gov.
Rhode Islandtelehealth & pricing rules
- • Rhode Island requires a live video consultation before a GLP-1 prescription.
- • Rhode Island allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Rhode Island: ~$322/mo (compounded options often lower, brand higher).